3 news items
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
OCUP
VTRS
10 May 24
™ by our partner Viatris, Inc. (Viatris) (NASDAQ:VTRS) was a major milestone
Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
OCUP
11 Apr 24
LASIK, PRK, SMILE, and RK) have been identified as one of the major sub-populations affected, the others being those who have night myopia (naturally
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
OCUP
11 Apr 24
keratorefractive surgery (including LASIK, PRK, SMILE, and RK) have been identified as one of the major sub-populations affected, the others being those who
- Prev
- 1
- Next